CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary

Journal: Nature Communications

Published: 2019-02-04

DOI: 10.1038/s41467-018-06958-9

Affiliations: 32

Authors: 36

Go to article
Institutions FC
Department of Biochemistry, McGill University, Canada 0.19
Rosalind and Morris Goodman Cancer Research Centre (GCRC), McGill University, Canada 0.14
NYU Laura and Isaac Perlmutter Cancer Center, United States of America (USA) 0.11
Genomics Core Facility, NKI, Netherlands 0.06
Predictive Biomarkers and Novel Therapeutic Strategies in Oncology, France 0.06
Cancer Therapeutics Program, OHRI, Canada 0.04
Department of Cellular and Molecular Medicine (CMM), uOttawa, Canada 0.04
Segal Cancer Centre, McGill University, Canada 0.03
School of Pharmaceutical Sciences (Shenzhen), SYSU, China 0.03
Research Institute, CHOP, United States of America (USA) 0.03
Department of Gynaecology and Obstetrics, MHH, Germany 0.03
Department of Pathology, U-M, United States of America (USA) 0.03
Research Institute of the McGill University Health Centre (RI-MUHC), Canada 0.03
Montreal Children's Hospital, Canada 0.02
Department of Pediatrics, McGill University, Canada 0.02
Department of Medical Genetics, McGill University, Canada 0.02
Lady Davis Institute for Medical Research (LDI), McGill University, Canada 0.01
Department of Pathology, McGill University, Canada 0.01
USC Children's Hospital Los Angeles (CHLA), United States of America (USA) 0.01
UCLA Department of Pathology and Laboratory Medicine, United States of America (USA) 0.01
Montreal Neurological Institute and Hospital (MNI), McGill University, Canada 0.01
Department of Laboratory Medicine and Pathobiology (LMP), U of T, Canada 0.01
University Health Network (UHN), U of T, Canada 0.01
Department of Human Genetics, McGill University, Canada 0.01
Cancer Research Program (CRP), McGill University, Canada 0.01
Sir Mortimer B. Davis Jewish General Hospital (SMBD JGH), Canada 0.01
Division of Experimental Medicine, McGill University, Canada 0.01
Gerald Bronfman Department of Oncology, McGill University, Canada 0.01